June 02, 2022
Alkermes Announces 2022 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental ...
June 01, 2022
Alkermes Presents ARTISTRY-1 Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Our company possesses a profound power to help shape a more inclusive and equitable society for all. We recognize the importance of our role. As Pride Month 2022 continues, see what our valued co-leaders have to say about their involvement with Pride@Work, our employee resource group for LGBTQ+ employees and allies.
Alkermes employees work in the laboratory, in the clinic and in the community, seeking to make a positive impact on the lives of people living with complicated and difficult-to-treat diseases. For many of our employees, this work is also part of their personal mission to help improve outcomes for patients, families and communities.
Now in its sixth year, the Alkermes Inspiration Grants® program is currently accepting applications for creative and innovative programs that will make a difference for patient communities. We are proud of the impact that previous grant recipients have made, and look forward to reviewing this year's proposals to address the needs of patients and communities.
Neuroscience
ALKS 1140 - Neurology
ALKS 2680 - Narcolepsy
Oncology
Nemvaleukin alfa* - Platinum-Resistant Ovarian Cancer
Nemvaleukin alfa - Mucosal Melanoma